PURA COVID-19 Update - Market Impact Study - Evolution and Sustained Growth - Coming CEO Acquisition Campaign Update
April 27 2020 - 01:44PM
InvestorsHub NewsWire
PURA COVID-19
Update #5 – Covid-19 CBD Market Impact Study – Evolution and 32%
Sustained Annual Growth
Dallas, TX -- April 27, 2020 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) today released its fifth
weekly Coronavirus Market update. With a market restart
anticipated to begin ramping up in the weeks to come, PURA is
making a careful study of the anticipated Covid-19 impact on the
overall CBD market. In short, the CBD market is anticipated
to sustain 31.9% annual growth through 2027 with CBD product
innovation and market channel evolution resulting from Covid-19
policy influences. Among other resources, PURA is looking at
the Data Bridge Market Research announced just last
week that includes a Covid-19 CBD Market
Analysis.
PURA
management anticipates the Coronavirus Pandemic to create both
issues and opportunities during and after the crisis.
Management plans to carefully continue to evaluate potential issues
and opportunities and maintain publishing weekly updates in order
to provide stakeholders with the most current information and
insight into management thinking throughout this highly fluid
business environment.
So far, the
impact to PURA has been minimal. PURA was fortunate enough to
execute a production run of its primary revenue generator, EVERx
CBD Sports Water, just prior to the shutdown and now, with light at
the end of the tunnel, it appears PURA will make it through to the
reopening of the economy with its current
inventory.
PURA continues
with its acquisition campaign launched earlier this year.
PURA recently announced initiating three new due
diligence efforts resulting from
new opportunities that management attributes to the impact of the
Coronavirus economic situation on businesses in general.
Puration’s CEO, Brian Shibley, plans to publish an update
later this week on PURA’s ongoing acquisition campaign highlighting
the company’s patented CBD extraction process
patent.
PURA
management continues to advance a prompt publishing of the annual
financial report for 2019. The company filed an extension in
conjunction with the current Covid-19 extension parameters and
plans to publish its financial report before the deadline for the
current extension
parameters.
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2023 to Mar 2024
Real-Time news about Puration Inc (CE) (OTCMarkets): 0 recent articles
More Puration Inc (PK) News Articles